Yujuan Yang1, Qingxia Zhang, Feng Xu, Lingyun Wu, Qi He, Xiao Li. 1. Department of Hematology, The Sixth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Jiaotong University, Shanghai, People's Republic of China.
Abstract
PURPOSE: BLU methylation status was investigated in bone marrow mononuclear cells from newly diagnosed myelodysplastic syndrome (MDS) patients and patients who received 5-aza-2'-deoxycytidine (decitabine) treatment so as to determine the effect of BLU in the pathogenesis of MDS. METHODS: Methylation-specific polymerase chain reaction and bisulfite sequencing were used to evaluate the methylation status of the promoter region of the BLU gene. BLU expression was investigated by using quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR) and Western blot analysis. RESULTS: Hypermethylation in the promoter region of BLU was detected in 34 of 79 (43%) newly diagnosed MDS patient samples and was significantly correlated with the loss of BLU mRNA and protein expression. There was a statistically significant difference in methylation frequency between the refractory anemia/refractory anemia with ringed sideroblasts/5q-syndrome (RA/RARS/5q-) group and the refractory anemia with excess blasts-1/-2 (RAEB-1/RAEB-2) group. A higher frequency of hypermethylation was observed in the intermediate-2/high-risk group compared to the low-risk/intermediate-1-risk group. The demethylating agent decitabine could partly reverse hypermethylation and restore the expression of the BLU gene. CONCLUSION: BLU promoter hypermethylation frequently occurs in MDS cases, especially in higher risk MDS cases, and is significantly associated with the downregulated expression of BLU. BLU gene re-expression was induced in some MDS cases undergoing decitabine therapy. BLU may play a substantial role in the development and etiology of MDS.
PURPOSE:BLU methylation status was investigated in bone marrow mononuclear cells from newly diagnosed myelodysplastic syndrome (MDS) patients and patients who received 5-aza-2'-deoxycytidine (decitabine) treatment so as to determine the effect of BLU in the pathogenesis of MDS. METHODS: Methylation-specific polymerase chain reaction and bisulfite sequencing were used to evaluate the methylation status of the promoter region of the BLU gene. BLU expression was investigated by using quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR) and Western blot analysis. RESULTS: Hypermethylation in the promoter region of BLU was detected in 34 of 79 (43%) newly diagnosed MDSpatient samples and was significantly correlated with the loss of BLU mRNA and protein expression. There was a statistically significant difference in methylation frequency between the refractory anemia/refractory anemia with ringed sideroblasts/5q-syndrome (RA/RARS/5q-) group and the refractory anemia with excess blasts-1/-2 (RAEB-1/RAEB-2) group. A higher frequency of hypermethylation was observed in the intermediate-2/high-risk group compared to the low-risk/intermediate-1-risk group. The demethylating agent decitabine could partly reverse hypermethylation and restore the expression of the BLU gene. CONCLUSION:BLU promoter hypermethylation frequently occurs in MDS cases, especially in higher risk MDS cases, and is significantly associated with the downregulated expression of BLU. BLU gene re-expression was induced in some MDS cases undergoing decitabine therapy. BLU may play a substantial role in the development and etiology of MDS.
Authors: Angelo Agathanggelou; Ashraf Dallol; Sabine Zöchbauer-Müller; Catherine Morrissey; Sofia Honorio; Luke Hesson; Tommy Martinsson; Kwun M Fong; Michael J Kuo; Po Wing Yuen; Eamonn R Maher; John D Minna; Farida Latif Journal: Oncogene Date: 2003-03-13 Impact factor: 9.867
Authors: Paulisally Hau Yi Lo; Alfred Chi Chung Leung; Wenjun Xiong; Simon Law; Fuh-Mei Duh; Michael I Lerman; Eric J Stanbridge; Maria Li Lung Journal: Cancer Lett Date: 2006-03-28 Impact factor: 8.679
Authors: Jian Gu; David Berman; Charles Lu; Ignacio I Wistuba; Jack A Roth; Marsha Frazier; Margaret R Spitz; Xifeng Wu Journal: Clin Cancer Res Date: 2006-12-15 Impact factor: 12.531
Authors: Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian Journal: Blood Date: 2006-04-11 Impact factor: 22.113
Authors: Y Cheng; R L K Y Ho; K C Chan; R Kan; E Tung; H L Lung; W L Yau; A K L Cheung; J M Y Ko; Z F Zhang; D Z Luo; Z B Feng; S Chen; X Y Guan; D Kwong; E J Stanbridge; M L Lung Journal: Oncogene Date: 2014-10-27 Impact factor: 9.867